Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China

Background: Tislelizumab, a new high-affinity programmed cell death protein-1 (PD-1) inhibitor, significantly prolonged the overall survival in pretreated non-small-cell lung cancer (NSCLC). This study aimed to assess the cost-effectiveness of tislelizumab versus docetaxel for this population in Chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jinhong, Su, Dan, Shang, Jingjing, Xu, Shan, Tang, Lidan, Sun, Zhiqiang, Liu, Guangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124929/
https://www.ncbi.nlm.nih.gov/pubmed/35614942
http://dx.doi.org/10.3389/fphar.2022.830380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124929/
https://www.ncbi.nlm.nih.gov/pubmed/35614942
http://dx.doi.org/10.3389/fphar.2022.830380

Ejemplares similares